GOLGA6D

Across TCGA pan-cancer cohorts, GOLGA6D RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated GOLGA6D data layer compared with 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GOLGA6D RNA is associated with worse overall survival. In most high-consensus cancer types, elevated GOLGA6D expression acts as an unfavorable survival marker, although some lineages such as SCLC and LIHC show a favorable association.

LUAD, MESO, and ACC are the cancer types where GOLGA6D RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.511	0.698	<.001	135	view →
MESO	OS	Tertile	III,IV	0.036	0.563	<.001	99	view →
ACC	DFS	Tertile	All	0.345	0.695	.005	87	view →
SCLC	DFS	Median	All	0.386	0.104	.001	46	view →
UCS	OS	Tertile	II,III,IV	0.205	0.622	.030	36	view →
READ	DFS	Tertile	II,III,IV	0.343	0.834	<.001	36	view →
THCA	DFS	Tertile	IV	0.348	0.809	.007	27	view →
KIRP	OS	Tertile	II,III,IV	0.148	0.771	<.001	27	view →
BRCA	OS	Tertile	III,IV	0.784	0.909	.019	18	view →
UCEC	DFS	Tertile	All	0.795	0.903	<.001	18	view →
LIHC	OS	Quartile	III,IV	0.849	0.449	.005	16	view →
KICH	DFS	Tertile	All	0.121	0.867	.023	15	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

GOLGA6D–LUAD (OS)

Open the LUAD breakdown →